Noninvasive Cancer Diagnostics: Technologies and Global Markets

Noninvasive Cancer Diagnostics: Technologies and Global Markets

Aug 2017 BCC Research Healthcare335 Pages Price :
$ 4950

Report Highlights
The global market for noninvasive cancer diagnostics was valued at $107.4 billion in 2016. This market is estimated to grow from nearly $114.6 billion in 2017 to $159.8 billion by 2022 with a compound annual growth rate (CAGR) of 6.9% for the period of 2017-2022.

Report Includes:
An overview of the global noninvasive cancer diagnostics market.
Analyses of global market trends, with data from 2016, estimates for 2017 and projections of compound annual growth rates (CAGRs) through 2022.
Analysis of the market by principle technology and by geography.
Detailed breakdown of advanced non-invasive approaches.
Coverage of segmentation of the cell-free DNA diagnostic methods.
A look at major factors driving the growth of the non-invasive cancer diagnostic and technologies market.
Profiles of major players in the industry.
Report Scope
The aim of this report is to initially conduct a review of the noninvasive cancer diagnostics products currently available; assess the market potential by clinical application; examine statistics on the incidence and mortality of cancer; review the issues facing the use of noninvasive cancer diagnostics; and review some of the latest developments into new and innovative noninvasive cancer diagnostic products, their technologies, and their intended clinical applications.

Key objectives are to conduct and provide an analysis of the market value, growth rates, market shares, and market development, as well as examine the market dynamics and market factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry, and the factors influencing the market shares of the major market suppliers as well as smaller indigenous manufactures in local markets. The emphasis of this report is to provide the reader with:

A detailed analysis of the revenues and forecasts for the global noninvasive cancer diagnostics market with a further, more detailed analysis and forecast of the revenues for the global market subdivided by major market subsegments by geographic region and finally by selected country.
A detailed analysis of the global market share, together with a further, more detailed analysis of the market share by geographic region and finally by selected country.
In addition, this analysis provides a:

Detailed review of the current products, their indications and availability for all the market segments identified.
Profile of the individual market subsegments within the major market segments analyzed and the distinguishing features of each of the market subsegments.
Review of the major market opportunities through the recognition of specific high-growth and emerging market opportunities.
Brief description of the historical development for each of the major market segments.
Profile of the leading suppliers of noninvasive cancer diagnostics and related products, together with related information about specific products.
The study will allow the reader to:

Evaluate the effect of strategic factors such as technology-driven change and industry consolidation for the noninvasive cancer diagnostics market.
Investigate the current market dynamics that are driving change in the noninvasive cancer diagnostics market.
Assess future growth opportunities in the noninvasive cancer diagnostics market.
Review the main products in each sector and plan a product entry strategy in line with the strengths and weaknesses of the competition.
Utilize the report to help realize a company's position in the marketplace and to provide insight into the future of the market and the opportunities that exist.

Table of Contents
Chapter 1: Introduction - 1
Study Goals and Objectives- 2
Scope of Report - 2
Methodology and Information Sources - 3
Primary Data and Information Gathering - 3
Secondary Data and Information Gathering - 4
Market Share Analysis and Market Forecast Prediction - 4
Geographic Breakdown - 5
Analyst's Credentials - 9
Related BCC Research Reports- 9
Chapter 2: Summary and Highlights - 11
Summary of Key Findings - 11
Diagnostic Imaging Segment - 13
Advanced Diagnostics Segment - 13
Conventional Segment - 14
Chapter 3: Market and Technology Review: Diagnostic Imaging - 16
Real-time In Vivo Cancer Diagnosis using Raman Spectroscopy - 16
In-Vivo Fluorescence Imaging in Personalized Cancer Diagnostics - 18
Direct Imaging - 18
Indirect Fluorescence Imaging - 19
Magnetic Resonance Imaging (MRI) Scans - 19
Development to the RF Subsystem - 22
Positron Emission Tomography (PET) Scan - 26
Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) - 29
Mammography - 31
Digital Mammography Systems - 32
Breast Tomosynthesis Systems - 35
Ultrasound - 36
Barium Swallow or Enema - 41
Bone Scans (MRI, CT and PET) - 42
Market Estimate - 42
Chapter 4: Market and Technology Review: Advanced Noninvasive Cancer
Diagnostic Assays and Technologies - 44
Introduction to Circulating Nucleic Acids (CNAs) - 46
Circulating Nucleic Acids as a Diagnostic Tool - 49
Circulating DNA as a Biomarker of Cancer - 50
Use of Circulating DNA for Prenatal Diagnosis (Conventional) - 50
Use of Circulating DNA for Prenatal Diagnosis (Noninvasive) - 51
Circulating RNA as a Biomarker of Cancer - 51
Methods Used for the Detection of Circulating Nucleic Acids - 55
Liquid Biopsy - 56
Janssen Diagnostics - 58
Roche Molecular Systems Inc. - 59
Genomic Health - 59
Foundation Medicine - 60
Veracyte - 60 -
Trovagene Inc. - 60
Myriad Genetics - 61
OncoCyte Corp. - 61
Illumina - 61
NeoGenomics Laboratories - 62
Biocept Inc. - 62
Vermillion Inc. - 63
Sysmex Inostics, a subsidiary of Sysmex Corp. - 63
Guardant Health - 63
Product Development and New Initiatives in Liquid Biopsy - 63
Molecular Cytogenetic/Gene Expression Studies - 65
Amplify and Detect Diminished Amounts of RNA Consistently - 68
Analyze Hundreds of Genes - 69
Proteomics and New Protein Markers - 69
Inside the ProteinChip System - 70
Proteome Pattern Recognition - 71
Next-Generation Sequencing (NGS) Studies - 72
Illumina Solexa System - 73
Roche 454 Sequencing - 73
Thermo Fisher Scientific Ion Personal Genome Machine (PGM) - 74
Thermo Fisher Scientific SOLiD (Sequencing by Oligonucleotide Ligation and Detection) - 74
Oxford Nanopore Technologies - 75
The Third-Generation Sequencer - 75
Clinical Acceptance of a New Diagnostic Assay - 76
Saliva-Based Oral Cancer Diagnostics - 78
Advanced Tissue Staining (Immunohistochemistry (IHC) and in situ Hybridization (ISH)) - 79
Optical Biopsy - 80
Market Estimate - 81
Chapter 5: Market and Technology Review: Conventional Noninvasive Cancer
Diagnostic Assays and Tests - 83
Pap Test and HPV Testing - 84
Tumor Biomarker Testing - 86
MammaPrint Specifications - 92
Genomic Healths Oncotype DX Breast Cancer Test - 93
The Prosigna Breast Cancer Prognostic Gene Signature Assay (formerly called the PAM50 test) - 94
Sales and Marketing Strategies for Cancer Tests - 95
Fecal Occult Blood Tests (FOBT) - 97
Digital Rectal Exam (DRE) - 100
Multigated Acquisition (MUGA) Scans - 100
Market Estimate - 101
Chapter 6: Incidence, Prevalence and Mortality Statistics for Cancer: A Global
Summary - 103
Cancer: The Disease - 103
Cancer: A Statistical Analysis of the Disease Incidence and Prevalence - 104
Incidence and Prevalence Rates for Major Cancer Types - 104
Regional Patterns of Cancer - 113
Europe - 113
North America - 113
Asia-Pacific- 115
Latin and Central America - 116
Middle East/Africa - 116
The Global Cancer Burden and Worldwide Cancer Risk Factors - 117
Tobacco Use and Statistics - 117
Alcohol Abuse and Cancer Statistics - 118
Obesity and Cancer Statistics - 118
Infectious Diseases and Cancer - 118
Inherited Genes/Diseases and Cancer - 119
Sun, U.V. and Cancer - 120
Hormones and Cancer - 120
Chapter 7: Noninvasive Cancer Diagnostics Market by Cancer Type - 122
Global Noninvasive Cancer Diagnostics Market, by Cancer Type - 122
Global Market Drivers - 127
Global Market Restraints - 131
Regional Noninvasive Cancer Diagnostics Market Assessment: North America - 133
Selected Market Drivers: North America - 133
Selected Market Restraints: North America - 136
Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type - 138
Regional Noninvasive Cancer Diagnostics Market Assessment: Europe - 140
Selected Market Drivers: Europe - 141
Selected Market Restraint: Europe - 143
Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type - 144
Regional Noninvasive Cancer Diagnostics Market Assessment: Asia-Pacific - 152
Selected Market Drivers: Asia-Pacific - 153
Selected Market Restraints: Asia-Pacific - 157
Regional Noninvasive Cancer Diagnostics Market Assessment: Central and Latin America - 162
Selected Market Drivers: Central and Latin America - 163
Selected Market Restraints: Central and Latin America - 166
Regional Noninvasive Cancer Diagnostics Market Assessment: Middle East/Africa - 171
Selected Market Drivers: Middle East/Africa - 174
Selected Market Restraints: Middle East/Africa - 175
Chapter 8: Market Analysis by Technology, End User and Market Share - 179
Global Noninvasive Cancer Diagnostics Market, by Technology - 179
Regional Noninvasive Cancer Diagnostics Market, by Technology: North America - 183
Regional Noninvasive Cancer Diagnostics Market, by Technology: Europe - 186
Regional Noninvasive Cancer Diagnostics Market, by Technology: Asia-Pacific - 189
Regional Noninvasive Cancer Diagnostics Market, by Technology: Central and Latin America - 191
Regional Noninvasive Cancer Diagnostics Market, by Technology: Middle East/Africa - 194
Global Noninvasive Cancer Diagnostics Market, by End-User - 196
General Clinical Reference Laboratories - 199
Market Share Analysis by Technology: Noninvasive Cancer Diagnostics Market - 200
Chapter 9: Technological Advances, Trends and Opportunities - 211
Key Technological Developments and Advances, Market Trends and Opportunities - 211
Developments and Advances, Trends and Opportunities in Diagnostic Imaging - 211
Developments and Advances, Trends and Opportunities in Advanced Noninvasive Approaches - 214
Developments and Advances, Trends and Opportunities in Screening Assays - 217
Opportunities for IVDMIA Companies - 220
Chapter 10: Regulatory and Legislative Requirements - 223
United States - 223
How are IVDs Classified? - 223
FDA Regulations Relating to Companion Diagnostics - 226
Laboratory Developed Tests (LDTs) - 227
Centers for Medicare & Medicaid Services (CMS) - 228
The 2010 Affordable Care Act - 229
Private Insurance - 229
Europe - 231
(General) Medical Device Directive, MDD (93/42/EEC) - 232
Active Implantable Medical Device Directive, AIMDD (90/383/EEC - 233
In Vitro Diagnostic Medical Device Directive, IVDMDD (98/79/EC) - 234
Proposal for Changes to the Medical Device Directive, MDD (93/42/EEC) - 234
Japan - 236
Marketing Authorization System - 237
China - 239
Overview of the Healthcare System - 239
Healthcare Reforms - 241
Healthcare Institutions - 241
India - 245
Overview of the Healthcare System - 245
Hospital Resources - 248
Population Statistics - 249
South Korea - 250
Brazil - 251
Background - 251
Regulatory and Legislative Requirements - 253
Market Entry and Reimbursement of Medical Devices: Brazil- 254
Argentina- 255
Background - 255
Government-funded Public Health Sector - 256
Social Health Insurance Sector - 256
Private Sector - 257
Regulatory and Legislative Requirements - 257
Mexico - 258
Legislation and Regulations Governing Medical Devices in Mexico - 259
Health Insurance Structure in Mexico - 260
Chapter 11: Patent Review of Key Technologies - 262
Microarray Patents - 263
LOAC Patents- 268
Clinical Next-Generation Sequencing (NGS) Patents - 270
Clinical NGS Patents Summary - 270
Clinical NGS Patents by Indication- 272
Chapter 12: Company Profiles - 275
Appendix A: Company Addresses and Contact Details - 335
Appendix B: Government Regulatory Agencies and Professional Organizations 349
Appendix C: Commonly Used Acronym Associated with Noninvasive Cancer
Diagnostics - 354
About BCC Research - 365
About BCC Research- 366
BCC Membership - 366
BCC Custom Research - 366

List of Table

List of Tables
Summary Table Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($
Millions) - 12
Table 1 Diagnostic Imaging Segment - 13
Table 2 Advanced Segment - 14
Table 3 Conventional Segment - 14
Table 4 Noninvasive Cancer Diagnostics Market Segmentation - 16
Table 5 Breast MRI Systems Currently Available - 20
Table 6 Wide Bore MRI Systems Currently Available - 21
Table 7 PET/CT Systems Currently Available - 27
Table 8 PET/MR Systems Currently Available - 31
Table 9 Key trends in (Digital Mammography Systems) - 33
Table 10 Digital Mammography Systems Currently Available - 33
Table 11 Breast Tomosynthesis Systems Currently Available - 36
Table 12 Benefits of Medical Ultrasound Imaging - 37
Table 13 Regulatory Approval for High-intensity Focused Ultrasound (HIFU) by Region - 38
Table 14 Ultrasound Systems Currently Available - 39
Table 15 Noninvasive Cancer Diagnostics Market Segmentation - 45
Table 16 Major Developments in Understanding Nucleic Acids and their Cellular Roles - 47
Table 17 Circulating Tumor-associated miRNAs as Potential Cancer Biomarkers - 52
Table 18 Key Elements for Business Competition in Gene Expression Profiling for Cancer - 65
Table 19 DNA Microarray Diagnostic Test Adoption Rate - 76
Table 20 Characteristics of in situ Hybridization Methods - 80
Table 21 Key Advantages of Optical Biopsy Systems - 81
Table 22 Noninvasive Cancer Diagnostics Market Segmentation - 84
Table 23 Key Drivers to Adoption of Biomarkers in Clinical Use - 88
Table 24 Key Barriers to Adoption of Biomarkers in Clinical Use - 88
Table 25 Tumor Biomarkers Currently in Common Clinical Use - 89
Table 26 MammaPrint: Key Features- 93
Table 27 Strategies for Marketing Cancer Diagnostic Products - 96
Table 28 Advantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT)) - 98
Table 29 Disadvantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT)) . 98
Table 30 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence, 2012 105
Table 31 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (In Men
and Women Combined) by Cancer Type, 2012 - 106
Table 32 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (Men) by
Cancer Type, 2012 - 109
Table 33 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (Women)
by Cancer Type, 2012 - 111
Table 34 Estimated Number of New Cancer Cases by Sex: United States, 2017 (%) - 114
Table 35 Estimated Number of Deaths from Cancer by Sex: United States, 2017 - 115
Table 36 Global Noninvasive Cancer Diagnostics Market, Through 2022 ($ Millions) - 122
Table 37 Global Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) . 123
Table 38 Global Noninvasive Cancer Diagnostics Market and Market Share, by Cancer Type, 2017 (%)
- 124
Table 39 Global Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%) - 126
Table 40 North American Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 134
Table 41 Sample Listing of Payers that Published Positive Coverage Policies for KRAS Testing - 135
Table 42 United States Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 138
Table 43 Canada Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) 140
Table 44 European Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
- 141
Table 45 Europe: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%) - 142
Table 46 France Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) 145
Table 47 Germany Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
- 146
Table 48 Italy Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) - 147
Table 49 Spain Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) - 148
Table 50 U.K. Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) - 149
Table 51 Benelux Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
- 150
Table 52 Scandinavia Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 151
Table 53 Rest of Europe Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 152
Table 54 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 153
Table 55 Asia-Pacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%) - 154
Table 56 China: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) - 160
Table 57 India: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 ($ Millions) - 160
Table 58 Japan: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 ($ Millions) - 161
Table 59 South Korea: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 161
Table 60 Rest of Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 162
Table 61 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through
2022 ($ Millions) - 163
Table 62 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%) ..... 164
Table 63 Argentina: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
- 168
Table 64 Brazil: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) .. 169
Table 65 Chile: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) ... 169
Table 66 Mexico: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)170
Table 67 Rest of Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type,
Through 2022 ($ Millions) - 171
Table 68 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 172
Table 69 Middle East/Africa: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%) ....... 173
Table 70 Middle East: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 176
Table 71 Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) . 177
Table 72 Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions) ... 180
Table 73 Global Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through
2022 ($ Millions) - 181
Table 74 Global Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies,
Through 2022 ($ Millions) - 182
Table 75 Global Noninvasive Cancer Diagnostics Market, by Conventional Noninvasive Cancer Screening
and Diagnostic Assays and Tests Technology, Through 2022 ($ Millions) - 182
Table 76 North America: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($
Millions) - 183
Table 77 North American: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies,
Through 2022 ($ Millions) - 184
Table 78 North American: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive
Technologies, Through 2022 ($ Millions) - 185
Table 79 North American: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology,
Through 2022 ($ Millions) - 185
Table 80 Europe: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions) . 186
Table 81 Europe: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through
2022 ($ Millions) - 187
Table 82 Europe: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies,
Through 2022 ($ Millions) - 188
Table 83 Europe: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through
2022 ($ Millions) - 188
Table 84 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($
Millions) - 189
Table 85 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies,
Through 2022 ($ Millions) - 190
Table 86 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies,
Through 2022 ($ Millions) - 190
Table 87 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through
2022 ($ Millions) - 191
Table 88 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Technology, Through
2022 ($ Millions) - 192
Table 89 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging
Technologies, Through 2022 ($ Millions) - 192
Table 90 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive
Technologies, Through 2022 ($ Millions) - 193
Table 91 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Screening Assay
Technology, Through 2022 ($ Millions) - 193
Table 92 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($
Millions) - 194
Table 93 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging
Technologies, Through 2022 ($ Millions) - 195
Table 94 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive
Technologies, Through 2022 ($ Millions) - 195
Table 95 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology,
Through 2022 ($ Millions) - 196
Table 96 Global Noninvasive Cancer Diagnostics Market, by End-User, Through 2022 ($ Millions) - 197
Table 97 Global Market Share for Diagnostic Imaging, Noninvasive Cancer Diagnostics, by Company,
2017 (%) - 201
Table 98 Global Market Share for Advanced Noninvasive Approaches, Noninvasive Cancer Diagnostics,
by Company, 2017 (%) - 202
Table 99 Global Market Share for Molecular Signature-Based Noninvasive Cancer Diagnostics, by
Company, 2017 (%) - 203
Table 100 Global Market Share for DNA Microarray-Based Noninvasive Cancer Diagnostics, by Company,
2017 (%) - 204
Table 101 Global Market Share for Cytogenetic/Gene Expression-Based Noninvasive Cancer Diagnostics,
by Company, 2017 (%) - 205
Table 102 Global Market Share for Circulating Nucleic Acid (CNA)-Based Noninvasive Cancer
Diagnostics, by Company, 2017 (%) - 206
Table 103 Global Market Share for Screening Assays, Noninvasive Cancer Diagnostics, by Company,
2017 (%) - 207
Table 104 Global Market Share for Fecal Occult Blood Test (FOBT)-Based Noninvasive Cancer
Diagnostics, by Company, 2017 (%) - 208
Table 105 Global Market Share for Tumor Biomarker Test-Based Noninvasive Cancer Diagnostics, by
Company, 2017 (%) - 209
Table 106 Principal Factors Influencing the Growth and Development of Noninvasive Cancer
Diagnostics, 2017 - 212
Table 107 Uses of Tumor Biomarkers in Drug Development - 219
Table 108 Utility of Biomarkers as Companion Diagnostics to Drug Development - 220
Table 109 Overview of Pharmaceutical Affair Law (PAL) and Japanese Medical Device Nomenclature
(JMDN) Codes and Related Codes according to the EU MDD - 237
Table 110 Number of Healthcare Institutions According to Ownership in China, 2010 - 242
Table 111 Total Number of Hospitals by Ranking in China, 2010 - 243
Table 112 Overview of Healthcare in India - 246
Table 113 DNA Microarray Patents by Region, 2002-2012 - 263
Table 114 Microarray-Related Proteomics Patents by Region, 2002 2012 - 264
Table 115 Microarray-Related Patents by Application and Title, 2017 - 264
Table 116 Patent Application and Title: Noninvasive Cancer Diagnostics, 2001 Present- 266
Table 117 LOAC-Related Proteomics Patents by Region, 2002 2012 - 269
Table 118 LOAC-Related Patents by Application and Title, 2013 2015 - 269
Table 119 Clinical Next Generation Sequencing Patents, 20022012 - 270
Table 120 Clinical NGS-Related Patents by Application and Title, 2013 2015 - 271
Table 121 Clinical NGS Patents by Indication, 20022012 - 272
Table 122 Abbott Laboratories: Company Financials, Through 2016 ($ Millions) - 278
Table 123 Bayer AG: Company Financials, Through 2016 ($ Millions) - 284
Table 124 bioMerieux S.A. Sales by Application, Through 2016 ($ Millions) - 289
Table 125 Exact Sciences Corp.: Company Financials, Through 2016 ($ Millions/%) - 295
Table 126 Hologic Inc.: Company Financials, 2015-2016 ($ Millions) - 302
Table 127 Illumina, Inc: Company Financials, 2014-2016 ($ Millions) - 305
Table 128 Myriad Genetics Inc. Financials, 2014 - 2016 ($ Millions) - 309
Table 129 Philips Healthcare Financials, Through 2016 ($ Millions) - 313
Table 130 Philips Group Financials by Segment, 2016 ($ Millions) - 314
Table 131 Qiagen N.V. Financials, Through 2016 ($ Millions) - 316
Table 132 Qiagen N.V. Financials by Region, Through 2016 ($ Millions) - 316
Table 133 Quest Diagnostics Financials, Through 2016 ($ Millions) - 320
Table 134 Roche Group Financials, Through 2016 ($ Millions) - 322 -
Table 135 Diagnostics Division Financials, 2015 and 2016 ($ Millions) - 322
Table 136 Thermo Fisher Scientific Inc. Financials, Through 2016 ($ Millions) - 330
Table 137 Company Addresses and Contact Details- 335
Table 138 Government Regulatory Agencies and Professional Organizations Associated with
Noninvasive Cancer Diagnostics - 349
Table 139 Commonly Used Acronym Associated with Noninvasive Cancer Diagnostics - 354

List of Chart

List of Figures
Summary Figure Global Noninvasive Cancer Diagnostics Market, by Technology, 2016-2022 ($ Millions)
- 12
Figure 1 Top Molecular CNA Characterization Techniques (%) - 57
Figure 2 Market Growth and Evolution of MDx Cancer Biomarkers - 95
Figure 3 Estimated Global Cancer Incidence Proportions by Major Sites, In Men and Women Combined,
2012 (%) - 108
Figure 4 Estimated World Cancer Incidence Proportions by Major Sites, In Men, 2012 (%) - 110
Figure 5 Estimated World Cancer Incidence Proportions by Major Sites, In Women, 2012 (%) - 112
Figure 6 Global Market Share for Noninvasive Cancer Diagnostics, by Cancer Type, 2017 (%) - 125
Figure 7 Global Noninvasive Cancer Diagnostics Market, by Region, 2017 (%) - 126
Figure 8 Average Number of New Cases per Year and Age-Specific Incidence Rates for all Cancers in the
U.K., 20122014 - 129
Figure 9 Europe: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%) - 142
Figure 10 Asia-Pacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%) - 154
Figure 11 Central and Latin America: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
- 165
Figure 12 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%) - 173
Figure 13 Global Noninvasive Cancer Diagnostics Market, by Technology Type, 2016-2022 ($ Millions)
- 180
Figure 14 Global Noninvasive Cancer Diagnostics Market, by End-User, 2016-2022 ($ Millions) - 198
Figure 15 Tumor Biomarker Developments and Market Applications (%) - 218
Figure 16 Private Health Insurance Coverage among Persons Under 65 in United States, 20072011
(Millions/Percent) - 231
Figure 17 The Chinese Healthcare System - 240

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 4950
$ 7128

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top